Title: Actimmune (interferon gamma-1b)

BCBSKS will review Prior Authorization requests

Prior Authorization Form:

Link to Drug List (Formulary):
https://www.bcbsks.com/drugs/

Professional
Original Effective Date: June 10, 2016
Revision Date(s): June 10, 2016;
August 1, 2017; September 12, 2018
Current Effective Date: June 10, 2016

Institutional
Original Effective Date: June 10, 2016
Revision Date(s): June 10, 2016;
August 1, 2017; September 12, 2018
Current Effective Date: June 10, 2016

DESCRIPTION
ACTIMMUNE® is part of a drug regimen used to treat Chronic Granulomatous Disease, or CGD. CGD is a genetic disorder, usually diagnosed in childhood, that affects some cells of the immune system and the body's ability to fight infections effectively. CGD is often treated (though not cured) with antibiotics, antifungals, and ACTIMMUNE.
ACTIMMUNE is also used to slow the worsening of severe, malignant osteopetrosis (SMO). SMO is a genetic disorder that affects normal bone formation and is usually diagnosed in the first few months after birth.

ACTIMMUNE is approved by the US Food and Drug Administration to treat two conditions: Chronic Granulomatous Disease (CGD) and Severe, Malignant Osteopetrosis (SMO). In patients with Chronic Granulomatous Disease (CGD), ACTIMMUNE helps to lower the risk and severity of serious infections. In patients with Severe Malignant Osteopetrosis (SMO), ACTIMMUNE can slow the worsening of the disease.

**Target Agent**
- Actimmune® (interferon gamma-1b)

**FDA Approved Indications and Dosage**
ACTIMMUNE is indicated for:
- Reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD).
- Delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO).

The recommended dosage of ACTIMMUNE administered subcutaneously, for the treatment of patients with CGD and SMO is shown in Table 1 below:

<table>
<thead>
<tr>
<th>Body Surface Area (m²)</th>
<th>Dose (mcg/m²)</th>
<th>Dose (International Units/m²)</th>
<th>Frequency</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greater than 0.5 m²</td>
<td>50 mcg/m²</td>
<td>1 million International Units/m²</td>
<td>Three times weekly (For example: Monday, Wednesday, and Friday)</td>
</tr>
<tr>
<td>Equal to or less than 0.5 m²</td>
<td>1.5 mcg/kg/dose</td>
<td></td>
<td>Three times weekly (For example: Monday, Wednesday, and Friday)</td>
</tr>
</tbody>
</table>

*Note that the above activity is expressed in International Units (1 million International Units/50 mcg). This is equivalent to what was previously expressed as units (1.5 million units/50 mcg).*
**POLICY**

A. Actimmune (interferon gamma-1b) may be considered *medically necessary* when dosed as per the FDA approved recommended dosage (see Table 1 above) for:

1. Reducing the frequency and severity of serious infections associated with Chronic Granulomatous Disease (CGD)
2. Delaying time to disease progression in patients with severe, malignant osteopetrosis (SMO)

B. Actimmune (interferon gamma-1b) is considered *experimental / investigational* for all other indications, including but not limited to idiopathic pulmonary fibrosis.

<table>
<thead>
<tr>
<th>FDA Labeled Contraindications</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Agent</strong></td>
</tr>
<tr>
<td>Actimmune (interferon gamma-1b)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Contraindicated as Concomitant Therapy</th>
</tr>
</thead>
</table>
| **Actimmune** (interferon gamma-1b)   | ▪ Concomitant use of drugs with neurotoxic, hematotoxic or cardiotoxic effects may increase the toxicity of interferons.  
▪ Avoid simultaneous administration of ACTIMMUNE with other heterologous serum protein or immunological preparations (e.g., vaccines). |

**RATIONALE**

ACTIMMUNE (Interferon gamma-1b), an interferon gamma, is a single-chain polypeptide containing 140 amino acids. Production of ACTIMMUNE is achieved by fermentation of a genetically engineered *Escherichia coli* bacterium containing the DNA which encodes for the recombinant protein.

Interferons bind to specific cell surface receptors and initiate a sequence of intracellular events that lead to the transcription of interferon-stimulated genes. The three major groups of interferons (alpha, beta, gamma) have partially overlapping biological activities that include immunoregulation such as increased resistance to microbial pathogens and inhibition of cell proliferation. Type 1 interferons (alpha and beta) bind to the alpha / beta receptor. Interferon gamma binds to a different cell surface receptor and is classified as Type 2 interferon. Specific effects of interferon gamma include the enhancement of the oxidative metabolism of macrophages, antibody dependent cellular
cytotoxicity (ADCC), activation of natural killer(NK) cells, and the expression of Fc receptors and major histocompatibility antigens.

Chronic Granulomatous Disease (CGD) is an inherited disorder of leukocyte function caused by defects in the enzyme complex responsible for phagocyte superoxide generation. ACTIMMUNE does not increase phagocyte superoxide production even in treatment responders.

In severe, malignant osteopetrosis (SMO) (an inherited disorder characterized by an osteoclast defect, leading to bone overgrowth, and by deficient phagocyte oxidative metabolism), a treatment-related enhancement of superoxide production by phagocytes was observed. ACTIMMUNE was found to enhance osteoclast function in vivo.

In both disorders, the exact mechanism(s) by which ACTIMMUNE has a treatment effect has not been established. Changes in superoxide levels during ACTIMMUNE therapy do not predict efficiency and should not be used to assess patient responses to therapy.

**Pharmacokinetics**

Pharmacokinetic studies in patients with CGD have not been performed. The intravenous, intramuscular, and subcutaneous pharmacokinetics of ACTIMMUNE have been investigated in 24 healthy male subjects following single-dose administration of 100 mcg/m² (twice the recommended dose for CGD and SMO patients). ACTIMMUNE is rapidly cleared after intravenous administration (1.4 liters/minute) and slowly absorbed after intramuscular or subcutaneous injection. After intramuscular or subcutaneous injection, the apparent fraction of dose absorbed was greater than 89%. The mean elimination half-life after intravenous administration of 100 mcg/m² in healthy male subjects was 38 minutes. The mean elimination half-lives for intramuscular and subcutaneous dosing with 100 mcg/m² were 2.9 and 5.9 hours, respectively. Peak plasma concentrations, determined by ELISA, occurred approximately 4 hours (1.5 ng/mL) after intramuscular dosing and 7 hours (0.6 ng/mL) after subcutaneous dosing. Multiple dose subcutaneous pharmacokinetic studies were conducted in 38 healthy male subjects. There was no accumulation of ACTIMMUNE after 12 consecutive daily injections of 100 mcg/m².

Interferon gamma was not detected in the urine of healthy human volunteers following administration of 100 mcg/m² of ACTIMMUNE by the intravenous, intramuscular and subcutaneous routes. *In vitro* perfusion studies utilizing rabbit livers and kidneys demonstrate that these organs are capable of clearing interferon gamma from perfusate.
Clinical Studies

Effects in Chronic Granulomatous Disease (CGD)
A randomized, double-blind, placebo-controlled trial of ACTIMMUNE (interferon gamma-1b) in patients with Chronic Granulomatous Disease (CGD), was performed to determine whether ACTIMMUNE administered subcutaneously on a three times weekly schedule could decrease the incidence of serious infectious episodes and improve existing infectious and inflammatory conditions in patients with CGD. One hundred twenty-eight eligible patients were enrolled in this trial including patients with different patterns of inheritance. Most patients received prophylactic antibiotics. Patients ranged in age from 1 to 44 years with the mean age being 14.6 years. The study was terminated early following demonstration of a highly statistically significant benefit of ACTIMMUNE therapy compared to placebo with respect to time to serious infection (p=0.0036), the primary endpoint of the investigation. Serious infection was defined as a clinical event requiring hospitalization and the use of parenteral antibiotics.

The final analysis provided further support for the primary endpoint (p=0.0006). There was a 67 percent reduction in relative risk of serious infection in patients receiving ACTIMMUNE (n=63) compared to placebo (n=65). Additional supportive evidence of treatment benefit included a twofold reduction in the number of primary serious infections in the ACTIMMUNE group (30 on placebo versus 14 on ACTIMMUNE, p=0.002) and the total number and rate of serious infections including recurrent events (56 on placebo versus 20 on ACTIMMUNE, p<=0.0001). Moreover, the length of hospitalization for the treatment of all clinical events provided evidence highly supportive of an ACTIMMUNE treatment benefit. Placebo patients required three times as many inpatient hospitalization days for treatment of clinical events compared to patients receiving ACTIMMUNE (1493 versus 497 total days, p=0.02). An ACTIMMUNE treatment benefit with respect to time to serious infection was consistently demonstrated in all subgroup analyses according to stratification factors, including pattern of inheritance, use of prophylactic antibiotics, as well as age. There was a 67 percent reduction in relative risk of serious infection in patients receiving ACTIMMUNE compared to placebo across all groups. The beneficial effect of ACTIMMUNE therapy was observed throughout the entire study, in which the mean duration of ACTIMMUNE administration was 8.9 months/patient.

Effects In Severe, Malignant Osteopetrosis (SMO)
A controlled, randomized trial in patients with severe, malignant osteopetrosis (SMO) was conducted with ACTIMMUNE administered subcutaneously three times weekly. Sixteen patients were randomized to receive either ACTIMMUNE plus calcitriol (n=11), or calcitriol alone (n=5). Patients ranged in age from 1 month to 8 years, mean 1.5 years. Treatment failure was considered to be disease progression as defined by 1) death, 2) significant reduction in hemoglobin or platelet counts, 3) a serious bacterial infection requiring antibiotics, or 4) a 50 dB decrease in hearing or progressive optic atrophy. The median time to disease progression was significantly delayed in the ACTIMMUNE plus
calcitriol arm versus calcitriol alone. In the treatment arm, the median was not reached. Based on the observed data, however, the median time to progression in this arm was at least 165 days versus the median of 65 days in the calcitriol alone arm. In an analysis which combined data from a second study, 19 of 24 patients treated with ACTIMMUNE plus or minus calcitriol for at least 6 months had reduced trabecular bone volume compared to baseline.

**CODING**

The following codes for treatment and procedures applicable to this policy are included below for informational purposes. Inclusion or exclusion of a procedure, diagnosis or device code(s) does not constitute or imply member coverage or provider reimbursement. Please refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage of these services as it applies to an individual member.

<table>
<thead>
<tr>
<th>HCPCS</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>J9216</td>
<td>Injection interferon, gamma-1b, 3 million units</td>
</tr>
</tbody>
</table>

**DIAGNOSES**

<table>
<thead>
<tr>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>D71</td>
<td>Functional disorders of polymorphonuclear neutrophils</td>
</tr>
<tr>
<td>J84.122</td>
<td>Idiopathic pulmonary fibrosis</td>
</tr>
<tr>
<td>Q78.2</td>
<td>Osteopetrosis</td>
</tr>
</tbody>
</table>

**REVISIIONS**

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>08-01-2017</td>
<td>Rationale section updated</td>
</tr>
<tr>
<td>09-12-2018</td>
<td>Description section updated</td>
</tr>
<tr>
<td></td>
<td>References updated</td>
</tr>
<tr>
<td></td>
<td>Note: Policy reviewed and approved by the Prime Therapeutics National Pharmacy and Therapeutics Committee on June 14, 2018.</td>
</tr>
</tbody>
</table>

**REFERENCES**